The Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States through Montefiore and a network of affiliates that includes hospitals and medical centers in the Bronx, Brooklyn and on Long Island.
ICT Role in 21st Century Education & its Challenges.pptx
Master of bioethics
1.
2. About Us
Albert Einstein College of Medicine, a part of Montefiore is
a premier, research-intensive medical school dedicated to
innovative biomedical investigation and to the
development of master of bioethics and compassionate
physicians and scientists. Inspired by the words of our
namesake, we have from our inception welcomed
students, faculty and staff from diverse backgrounds who
strive to enhance human health in the community and
beyond. This is an attribute in which Albert Einstein took
great pride when consenting to the use of his name in
conjunction with the medical school.
At the core of the Einstein-Montefiore mission is the
pursuit of social justice in meeting the healthcare needs of
all individuals, including those from underserved
communities.
3. Education
Einstein’s M.D. program prepares tomorrow’s
physicians to excel in both the science and the art of
medicine by combining the pursuit of scientific
excellence with compassionate and humanistic care
and the social mission to improve human health
through engagement in our local, national, and
global communities. Our Graduate Programs in the
Biomedical Sciences train some of today’s brightest
students to become the next generation of leading
scientific researchers, while our Medical Scientist
Training Program (resulting in both M.D. and Ph.D.
degrees) embraces a comprehensive "bench to
bedside" philosophy to nurture the development of
well-rounded physician-scientists. In all, the College
of Medicine offers six graduate degree programs.
4. Research
Boosting Liver Detoxification—The liver is essential for
removing molecules such as drugs and toxins from the
bloodstream—a job done by hepatocytes, cells that comprise
most of the liver’s mass and remove these compounds from the
blood using specialized transporter proteins. Allan Wolkoff,
M.D., has received a $2.3 million, five-year renewal grant from
the NIH to continue his research on improving the liver’s
detoxification ability. In a healthy liver, these transporter
proteins are in a balanced state as they travel between the cell
surface of hepatocytes and vesicles within the cells. But disease
can disrupt this equilibrium, causing so few transporters at the
cell surface that toxic compounds can accumulate in the blood.
Dr. Wolk off is studying the molecular mechanisms that govern
transporter trafficking and the cell-surface expression of
transporter proteins. His research may lead to strategies for
improving the liver-mediated clearance of chemicals from the
circulation.
5. Health
Editors' Note: February 29 marks the ninth
annual Rare Disease Day, a worldwide event
devoted to raising awareness of more than 6,500
rare diseases, of which less than 5 percent have
any available treatment. In September 2015,
Montefiore assumed operational and financial
control of Einstein. Together they advance
clinical and translational research to accelerate
the pace at which new discoveries become the
treatments and therapies that benefit patients.
